Compare HAS & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAS | NBIX |
|---|---|---|
| Founded | 1923 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 13.2B |
| IPO Year | 1994 | 1996 |
| Metric | HAS | NBIX |
|---|---|---|
| Price | $95.33 | $131.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 22 |
| Target Price | $109.73 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 4.67 |
| Revenue | ★ $5,365,900,000.00 | $161,626,000.00 |
| Revenue This Year | $5.38 | $24.73 |
| Revenue Next Year | $6.48 | $13.14 |
| P/E Ratio | ★ N/A | $28.21 |
| Revenue Growth | 13.06 | ★ 977.51 |
| 52 Week Low | $60.33 | $108.47 |
| 52 Week High | $106.98 | $160.18 |
| Indicator | HAS | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 53.32 |
| Support Level | $86.85 | $124.62 |
| Resistance Level | $98.63 | $135.30 |
| Average True Range (ATR) | 3.12 | 3.41 |
| MACD | 0.25 | 0.17 |
| Stochastic Oscillator | 63.27 | 70.73 |
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Peppa Pig, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and has since divested noncore lines from the tie-up. Furthermore, the addition of Dungeons & Dragons Beyond in 2022 offers the firm access to 19 million digital tabletop players.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.